OTRK vs. MGRX, BRTX, MRAI, GBNHF, CORBF, ARA, TVTY, DVA, FMS, and SHC
Should you be buying Ontrak stock or one of its competitors? The main competitors of Ontrak include Mangoceuticals (MGRX), BioRestorative Therapies (BRTX), Marpai (MRAI), Greenbrook TMS (GBNHF), Global Cord Blood (CORBF), American Renal Associates (ARA), Tivity Health (TVTY), DaVita (DVA), Fresenius Medical Care (FMS), and Sotera Health (SHC).
Ontrak (NASDAQ:OTRK) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.
Ontrak has a net margin of -186.35% compared to Mangoceuticals' net margin of -1,068.72%. Ontrak's return on equity of -304.29% beat Mangoceuticals' return on equity.
13.0% of Ontrak shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 1.6% of Ontrak shares are held by company insiders. Comparatively, 39.3% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Mangoceuticals has lower revenue, but higher earnings than Ontrak.
In the previous week, Mangoceuticals had 2 more articles in the media than Ontrak. MarketBeat recorded 4 mentions for Mangoceuticals and 2 mentions for Ontrak. Mangoceuticals' average media sentiment score of 0.96 beat Ontrak's score of 0.44 indicating that Mangoceuticals is being referred to more favorably in the news media.
Ontrak received 37 more outperform votes than Mangoceuticals when rated by MarketBeat users.
Ontrak currently has a consensus target price of $4.00, indicating a potential upside of 1,493.63%. Given Ontrak's higher probable upside, research analysts clearly believe Ontrak is more favorable than Mangoceuticals.
Ontrak has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
Summary
Ontrak beats Mangoceuticals on 8 of the 14 factors compared between the two stocks.
Get Ontrak News Delivered to You Automatically
Sign up to receive the latest news and ratings for OTRK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OTRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
